Related Experiment Video
Updated: Apr 22, 2026
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Inhaled antibiotics: dry or wet?
Harm A W M Tiddens1, Aukje C Bos2, Johan W Mouton3
1Erasmus MC-Sophia Children's Hospital, Dept of Pediatric Pulmonology and Allergology, Rotterdam, The Netherlands Erasmus MC, Dept of Radiology, Rotterdam, The Netherlands h.tiddens@erasmusmc.nl.
Abstract:
Dry powder inhalers (DPIs) delivering antibiotics for the suppressive treatment of Pseudomonas aeruginosa in cystic fibrosis patients were developed recently and are now increasingly replacing time-consuming nebuliser therapy. Noninferiority studies have shown that the efficacy of inhaled tobramycin delivered by DPI was similar to that of wet nebulisation. However, there are many differences between inhaled antibiotic therapy delivered by DPI and by nebuliser. The question is whether and to what extent inhalation technique and other patient-related factors affect the efficacy of antibiotics delivered by DPI compared with nebulisers. Health professionals should be aware of the differences between dry and wet aerosols, and of patient-related factors that can influence efficacy, in order to personalise treatment, to give appropriate instructions to patients and to better understand the response to the treatment after switching. In this review, key issues of aerosol therapy are discussed in relation to inhaled antibiotic therapy with the aim of optimising the use of both nebulised and DPI antibiotics by patients. An example of these issues is the relationship between airway generation, structural lung changes and local concentrations of the inhaled antibiotics. The pros and cons of dry and wet modes of delivery for inhaled antibiotics are discussed.
Insights
Dry powder inhalers (DPIs) offer a faster alternative to nebuliser therapy for cystic fibrosis patients. Patient technique and individual factors significantly impact the effectiveness of both DPI and nebuliser antibiotic delivery.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Biomedical Engineering
Background:
- Dry powder inhalers (DPIs) are emerging as a more efficient alternative to traditional nebuliser therapy for antibiotic delivery in cystic fibrosis (CF) patients.
- Studies indicate noninferiority of inhaled tobramycin via DPI compared to nebulisation for treating Pseudomonas aeruginosa.
- Significant differences exist between DPI and nebuliser delivery systems, necessitating a deeper understanding of their comparative efficacy.
Purpose of the Study:
- To explore how inhalation technique and patient-specific factors influence the efficacy of antibiotics delivered via DPI versus nebulisers.
- To highlight the importance of understanding aerosol delivery differences for personalized CF treatment.
- To provide guidance for healthcare professionals on optimizing inhaled antibiotic therapy.
Main Methods:
- Review of current literature on aerosol therapy and inhaled antibiotic delivery systems.
- Analysis of factors influencing drug deposition in the lungs, including airway generation and structural lung changes.
- Comparative discussion of the advantages and disadvantages of dry powder inhalers and nebulisers for antibiotic administration.
Main Results:
- While noninferiority studies show similar efficacy for inhaled tobramycin, patient-related factors and inhalation technique can significantly alter outcomes.
- Differences in aerosol characteristics (dry vs. wet) impact local antibiotic concentrations within the airways.
- Understanding these variables is crucial for effective treatment personalization and patient instruction.
Conclusions:
- Healthcare providers must be aware of the nuances between DPI and nebuliser therapies to tailor treatment effectively.
- Personalized patient instruction and consideration of individual factors are key to optimizing inhaled antibiotic efficacy.
- Further research into optimizing aerosol delivery methods can improve outcomes for cystic fibrosis patients.
More Related Videos
04:59Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Related Concept Videos
01:23Inhaled Medications
01:18Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
01:15Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...